The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 934 GLP-1 Medications articles
Analyses of GLP-1 receptor agonists for weight management show clinically significant weight loss compared to placebo. However, long-term safety and potential side effects remain uncertain. Financial ties influencing study results are also a concern.
The entertainment industry is seeing a trend of slimmer celebrities, leading to discussions about the role of medications like Ozempic. This shift raises questions about evolving beauty standards and body positivity in Hollywood.
WeightWatchers intends to offer Novo Nordisk's oral Wegovy upon potential FDA approval. This strategic move occurs amidst a competitive weight-loss drug market, aiming to provide a convenient alternative to injections. The FDA is also expediting GLP-1 treatments to improve access.
The demand for weight-loss drugs is surging. New medications promise increased effectiveness and easier administration, including oral options. Several pharmaceutical companies are developing improved injectable drugs.
Hair loss, or 'GLP-1 shedding,' can be a concerning side effect for those using GLP-1 drugs. However, solutions are available to effectively address this issue. A dermatologist provides insights into managing hair loss associated with these medications.
Research indicates that GLP-1 therapies offer enhanced weight benefits compared to metformin in adolescents diagnosed with type 2 diabetes. The study highlights comparable glycemic control with GLP-1 drugs but superior weight reduction.
A recent report highlights the states with the highest obesity rates and analyzes the increasing use of GLP-1 medications such as Ozempic. The data reveals regional trends and potential impacts on public health, with higher usage in the South, Midwest, and Appalachia.
Scientists are exploring a way to enable the body's own production of glucagon-like peptide-1 (GLP-1), the hormone mimicked by weight-loss drugs. Two biotech startups are developing gene therapies to reprogram cells to produce GLP-1, potentially replacing regular injections.
OrderlyMeds, an Atlanta-based telemedicine startup, has garnered over 90,000 customers in under two years, all seeking more effective and personalized weight loss assistance. The company emerged from Founder and CEO Chris Spears' own experience with GLP-1s.
